REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options and Restricted Stock Units
14/06/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240614:nRSN4058Sa&default-theme=true
RNS Number : 4058S MaxCyte, Inc. 14 June 2024
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options and Restricted Stock Units
ROCKVILLE, MD, June 14, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that on 11 June 2024, a total of 325,608 options ("Option
Grants") in respect of common stock in the Company ("Common Stock"), and
170,936 restricted stock units ("RSU"s) were granted to PDMRs who are
non-executive directors of the Company. These Options Grants and RSUs were
made pursuant to the Company's Equity Grant Policy for non-executive
directors.
Details of the Option Grants are given below:
Option Grants to PDMRs
Al-Wakeel, Yasir 40,701
Brooke, Will 40,701
Balthrop, Patrick 40,701
Douglas, Richard 40,701
Erck, Stanley 40,701
Hemrajani, Rekha 40,701
Johnston, John 40,701
Mandell, Art 40,701
Total 325,608
Option Grants for non-executive directors fully vest at the end of twelve (12)
months after date of grant. (1 year cliff until fully vested).
The Options Grants have an exercise period of 10 years from date of grant, at
which time they will expire, and have an exercise price equal to the closing
price of MaxCyte's stock on 11 June 2024, of $4.68 on the United States Nasdaq
Stock Exchange.
Details of the RSUs are given below:
Option Grants to PDMRs
Al-Wakeel, Yasir 21,367
Brooke, Will 21,367
Balthrop, Patrick 21,367
Douglas, Richard 21,367
Erck, Stanley 21,367
Hemrajani, Rekha 21,367
Johnston, John 21,367
Mandell, Art 21,367
Total 170,936
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology, as
well as technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com
(https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/MaxCyte_info) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com (mailto:ir@maxcyte.com)
Nominated Adviser and Joint Corporate Broker
Panmure Gordon +44 (0)20 7886 2500
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)
Mary-Jane Elliott
Chris Welsh
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name a) Yasir Al-Wakeel
b) Will Brooke
c) Patrick Balthrop
d) Richard Douglas
e) Stanley Erck
f) Rekha Hemrajani
g) John Johnston
h) Art Mandell
2 Reason for the notification
a) Position/status a) Non-Executive Director
b) Non-Executive Director
c) Non-Executive Director
d) Non-Executive Chairman
e) Non-Executive Director
f) Non-Executive Director
g) Non-Executive Director
h) Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Grant of options of common stock
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
a) $4.68 40,701
b) $4.68 40,701
c) $4.68 40,701
d) $4.68 40,701
e) $4.68 40,701
f) $4.68 40,701
g) $4.68 40,701
h) $4.68 40,701
d) Aggregated information
- Aggregated volume 325,608
- Price $4.68
e) Date of the transaction 11 June 2024
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name a) Yasir Al-Wakeel
b) Will Brooke
c) Patrick Balthrop
d) Richard Douglas
e) Stanley Erck
f) Rekha Hemrajani
g) John Johnston
h) Art Mandell
2 Reason for the notification
a) Position/status a) Non-Executive Director
b) Non-Executive Director
c) Non-Executive Director
d) Non-Executive Chairman
e) Non-Executive Director
f) Non-Executive Director
g) Non-Executive Director
h) Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common Stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Grant of restricted stock units
c) Price(s) and volume(s)
Exercise Price(s) Volume(s)
i) N/A 40,701
j) N/A 40,701
k) N/A 40,701
l) N/A 40,701
m) N/A 40,701
n) N/A 40,701
o) N/A 40,701
p) N/A 40,701
d) Aggregated information
- Aggregated volume 170,936
- Price No exercise price for the RSUs
e) Date of the transaction 11 June 2024
f) Place of the transaction US Stock Exchange, Nasdaq
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHDBGDLIGBDGSXRecent news on MaxCyte
See all newsREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - TR-1: Notification of major holdings
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Total Voting Rights
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Publication of Annual Report
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options and Restricted Stock Units
Announcement